3 recruiting, 2 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Terminated 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow CCNE1 Amplification: new trials by email Literature Review of CCNE1 Amplification trials Research Report on CCNE1 Amplification
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-30 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Study of AVZO-021 in Patients With Advanced Solid Tumors AVZO-021, Palbociclib, Fulvestrant - Advanced Solid Tumor, HR+/HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 430 | 2023-08-30 | 2026-09-28 |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer INX-315, Fulvestrant, Abemaciclib - Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Incyclix Bio | 150 | 2023-03-28 | 2026-04-01 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors BLU-222, Carboplatin, Ribociclib - Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Terminated | Blueprint Medicines Corporation | 50 | 2022-04-07 | 2025-11-28 |
Endometrial Neoplasms (4) · Ovarian Neoplasms (4) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Diseases (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Ovarian Epithelial (1) · Carcinosarcoma (1) · Fallopian Tube Neoplasms (1)
Adnexal Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Gonadal Disorders (5) · Neoplasms (5) · Neoplasms by Site (5) · Ovarian Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Breast Diseases (4)
Fulvestrant (3) · Carboplatin (2) · abemaciclib (2) · ribociclib (2) · Doxorubicin (1) · Letrozole (1) · Paclitaxel (1) · palbociclib (1) · sacituzumab govitecan (1)
NiKang Therapeutics, Inc. (2) · Avenzo Therapeutics, Inc. (1) · Blueprint Medicines Corporation (1) · Incyclix Bio (1)
United States (5) · Australia (2) · Italy (1) · South Korea (1) · United Kingdom (1)